New anti-diabetes agents (glucagon-like peptide-1 receptor (GLP-1R), agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose transporter-2 (SGLT-2) inhibitors) were found to have renal protective effects via anti-hypertensive, hemodynamic stabilization, anti-inflammatory, and anti-oxidative actions [13,14,15,16]. Here, DPP4 is linked to diabetes mellitus.